

# Clinicopathological features and prognostic implications of loss of K5 and gain of K1, K8 and K18 in oral potentially malignant lesions and squamous cell carcinomas: An immunohistochemical analysis

Sharada Sawant, Milind Vaidya, Devendra Chaukar, Prakash Gangadaran, Archana Kumari Singh, Siddheshwar Rajadhyax, Sadhana Kannan, Padmavathi A., Shubhada Kane, Sandeep Pagare, Ranganathan Kannan, Anil D'Cruz

## ABSTRACT

**Aims:** To analyze alterations in the expression and localization patterns of keratins-K1, K5, K8 and K18 using immunohistochemistry and correlate with clinicopathological parameters of patients with oral potentially malignant lesions and squamous cell carcinomas to evaluate diagnostic and prognostic implications of loss and gain of keratins. **Methods:** Altered keratin

expression pattern was investigated using immunohistochemistry in tissues of oral normal mucosa (n=10), leukoplakia (n=50), submucous fibrosis (n=67) and tumor respective cut-margins (n=304). The prognostic significance was determined by correlating the values of these two events singly as well as in different permutations and combinations with clinicopathological parameters using univariate and multivariate analyzes. **Results:** Loss of K5 and aberrant

Sawant Sharada<sup>1</sup>, Vaidya Milind<sup>2</sup>, Chaukar Devendra<sup>3</sup>, Gangadaran Prakash<sup>4</sup>, Singh Archana<sup>5</sup>, Rajadhyax Siddheshwar<sup>6</sup>, Kannan Sadhana<sup>7</sup>, Padmavathi A<sup>8</sup>, Kane Shubhada<sup>9</sup>, Pagare Sandeep<sup>10</sup>, Kannan Ranganathan<sup>11</sup>, D'Cruz Anil<sup>12</sup>

**Affiliation:** <sup>1</sup>MSc, Scientific Officer, Vaidya Lab., Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, 410 210, Maharashtra, India; <sup>2</sup>PhD, Scientific Officer, Vaidya Lab., Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, 410 210, Maharashtra, India; <sup>3</sup>MS, Professor and Surgeon, Oral Surgery, Head and Neck Unit, Tata Memorial Hospital, Parel, Mumbai, 400 012, Maharashtra, India; <sup>4</sup>MSc, Post graduate student, Department of Nuclear Medicine, Kyungpook National University, Daegu, Republic of Korea, 700-721; <sup>5</sup>MSc, Research Assistant, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, 410 210, Maharashtra, India; <sup>6</sup>MSc, Research Assistant, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, 410 210, Maharashtra, India; <sup>7</sup>MSc, Program Manager, Epidemiology and Clinical Trials Unit, Clinical Research Centre, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Kharghar, Navi Mumbai, Maharashtra, India; <sup>8</sup>MSc, ad-hoc statistician, Epidemiology and Clinical Trials Unit, Clinical Research Centre, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Kharghar, Navi Mumbai, Maharashtra, India; <sup>9</sup>MD, Professor and Pathologist, Pathology Department, Tata Memorial Hospital, Parel, Mumbai, 400 012, Maharashtra, India; <sup>10</sup>MDS, Professor and Chief, Department of Oral Medicine & Radiology, D.Y. Patil Dental College and Hospital, Sector 7, Nerul, Navi-Mumbai-400706, Maharashtra, India; <sup>11</sup>MDS, Professor and Chief, Department of Oral and Maxillofacial Pathology, Ragas Dental College and Hospital, Uthandi, 600096 Chennai, India; <sup>12</sup>MS, Professor and Chief, Oral Surgery, Head and Neck Unit, Tata Memorial Hospital, Parel, Mumbai, 400 012, Maharashtra, India.

**Corresponding Author:** Sharada Sawant, Vaidya Lab., Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai 410 210, Maharashtra, India; Tel: +91 22 27405134, Fax: +91 22 27405085; Email: sssawant@actrec.gov.in

Received: 14 July 2014  
Accepted: 14 August 2014  
Published: 25 December 2014

expression of K1, K8 and K18 were seen in oral premalignant lesions as well as tumor tissues in comparison to normal oral mucosal tissues. Non-expression of K5 ( $p=0.003$ ), and aberrant expression of K1 ( $p<0.001$ ), K8 ( $p=0.001$ ), and K18 ( $p=0.004$ ), independently significantly correlated with clinicopathological progressive grade of oral premalignant disorders as well as some of the clinicopathological factors of patients with oral cancer. The univariate and multivariate analysis showed the significance of combination of keratin markers (K1, K8, K18) on overall survival and local recurrence free survival of patients with oral cancer. The number of markers combined together has increased the risk of recurrence significantly ( $p<0.0001$ ). Conclusion: These findings suggest, loss and gain of keratins could serve as surrogate markers for the diagnosis of oral potentially malignant disorders and may also have prognostic value in patients with oral cancer.

**Keywords:** Keratin biomarkers, Leukoplakia, Oral squamous cell carcinomas, Submucous fibrosis

#### How to cite this article

Sharada S, Milind V, Devendra C, Prakash G, Archana S, Siddheshwar R, Sadhana K, Padmavathi A, Shubhada K, Sandeep P, Ranganathan K, Anil DC. Clinicopathological features and prognostic implications of loss of K5 and gain of K1, K8 and K18 in oral potentially malignant lesions and squamous cell carcinomas: An immunohistochemical analysis. Edorium J Tumor Bio 2014;1:1–22.

Article ID: 100001T09SS2014

\*\*\*\*\*

doi:10.5348/T09-2014-1-OA-1

## INTRODUCTION

Oral squamous cell carcinoma (OSCC) is the sixth largest group of malignancies worldwide [1] and the single largest malignancy in males in the Indian subcontinent [2]. In Indian scenario, major contributory factors for the high incidence of oral cancer are the habits of chewing tobacco, areca nut, and other allied products coupled with alcohol consumption, lower socioeconomic status, and poor oral hygiene [3]. It is well accepted fact that in India, most invasive oral cancers arise from potentially

malignant disorders of oral mucosa such as leukoplakia, erythroplakia and submucous fibrosis (SMF).

The incidence of oral cancer in subjects with tobacco habits is 50-fold higher as compared to tobacco non-users [3]. The follow-up data show that the risk of malignant transformation of oral leukoplakia varies widely between 0.5% and 20% [4], whereas for SMF, it ranges between 4.5% and 7.6% [5]. Dysplasia is being currently used as standard predictive parameter to predict the risk for the conversion of potentially malignant lesions into frank malignancy [5, 6]. However, histopathological assessment is rather subjective [7] and the existing imaging modalities are also not sensitive enough to predict the risk of malignant conversion [8].

Despite the advances in surgical and therapeutic modalities, the prognosis for patients with OSCC remains poor and the survival rate is less than 50% [9]. It is known that local recurrence and regional lymph node metastasis are major contributory factors for poor survival of oral cancer patients and have proved to be major hurdle in the management of disease. More than 40% oral cancer patients die as a result of uncontrolled local recurrence [10]. Currently, treatment decisions are based on established clinicopathological parameters like the TNM classification. However, tumor progression seems to be a multifactorial and multistep process [11], where, accumulation of genetic defects is reflected into molecular alterations which further lead to the development of cancer. Since molecular changes occur before cellular or clinical changes are evident, detection of these molecular changes would ideally allow early diagnosis/prognosis of the disease [12]. A number of molecular markers have been proposed in the past for prognostication of oral cancer. However, their prognostic value is still not quite clear [10, 13]. Considering all these facts, it is necessary to develop other modalities as an adjunct to histodiagnosis for predicting the malignant potential of high-risk lesions as well as for the prognostication of patients with OSCC.

Keratins (K) are epithelia predominant intermediate filament (IF) proteins which are expressed in a differentiation dependent, site specific and paired manner. The keratin pair of 5 and 14 is found mainly in the basal cell layer and is associated with the proliferative potential of these cells, while, the intermediary cell layers show expression of high molecular weight keratin pair of 4/13 or 1/10, which are regarded as markers of cellular differentiation. In contrast, low molecular weight keratin pair of 8/18 is normally express in glandular epithelia. K1, K8 and K18 are aberrantly expressed in buccal mucosa while K8 and K18 are aberrantly expressed in tongue tissues during oral carcinogenesis.

A number of groups have studied keratin expression profile in human oral precancer as well as cancer and some consistent patterns of keratin expression have emerged from these studies [14–20]. Many of these alterations show a potential to be used as predictive markers for human oral cancer.

In our previous studies, we have demonstrated non-expression of K5 and aberrant expression of K1, K8 and K18 in both oral mucosal premalignant lesions and SCC [14, 18–20]. These results clearly indicated the possibility of using these changes as predictive biomarkers for both oral precancerous lesions and SCC. It was necessary to use adequate sample size so as to statistically evaluate clinical significance of non-expression/aberrant expression of these proteins because of the limited sample size used in the previous studies. Previous study was conducted by one and two dimensional gel electrophoresis along with western blotting. It is difficult to prove non-expression of a protein using standard immunochemical techniques. Therefore, K5 non-expression was also studied using reverse transcriptase-polymerase chain reaction assay [14]. Although, immunohistochemistry (IHC) is a semi-quantitative technique, it gives the information about the alterations in the localization of protein which has more clinical value. Availability of more sensitive techniques and highly specific antibodies enable immunolabeling more specific.

Hence, in this study our aim was to analyze alterations in the expression and localization patterns of K1, K5, K8 and K18 and correlate with clinicopathological parameters of patients with oral premalignant lesions and SCC to evaluate diagnostic and prognostic implications of altered keratins expression pattern.

Our results show significant correlation of loss of K5 and gain of K1, K8, and K18 with clinical and histopathological grade of disease progression in hyperplasia/dysplasia samples. Combinations of the aberrantly expressed keratins—K1, K8 and K18 (any 1 positive, any 2 positive, and all positive) significantly correlated with overall survival and recurrence free survival of OSCC patients. Further, we also noticed the trend that the risk of tumor recurrence increased, with increased number of markers combined together ( $p < 0.001$ , sts test, trend, STATA 11.0).

## MATERIALS AND METHODS

### Patients and Tissue Specimens

Biopsy specimens from buccal leukoplakia (n=52) and SMF of buccal mucosa (BM, n=67) were collected from D.Y. Patil Dental College, Navi, Mumbai, India and Nair Dental Hospital, Mumbai, India. Paraffin embedded blocks of normal BM (n=10) were collected from Ragas Dental College, Chennai, India. Normal BM tissues were obtained during third molar tooth extraction. Surgically, excised 304 tumor tissues (SCC of tongue, n=144, SCC of BM, n=160) with their respective cut margin tissues (1 cm away from the tumor free borders), metastatic lymph nodes (n=9), and non-metastatic lymph nodes (n=5) were collected from Tata Memorial Hospital (TMH), Mumbai, India before commencement of any

anticancer therapy. All subjects with premalignant lesions and about 90% patients with oral SCC had habits of chewing tobacco, areca nut and/or alcohol along with other multiple habits. This study was approved by the Human Ethics Committees of the respective Institutional Review Boards. Informed consent was obtained from the patients/normal individuals before enrolling them in this study.

### Clinical and Histopathological Information of Patients

The clinical and histopathological information of patients were collected from the case files and electronic medical records of the respective institutions (Table 1 and Table 2). The clinical follow-up of oral cancer patients was done for 56 months (median 25 months) in the clinic of TMH. During the follow-up, data related to recurrence of the tumor and survival status of the patients was collected.

Five micrometers thick sections from 10% buffered formalin fixed and paraffin embedded tissues were stained with Hematoxylin and Eosin (H&E), and histopathological grading [3] was done by two independent pathologists. Histopathologically, it was confirmed that all tumors were squamous cell carcinomas (SCC). Subsequent to H&E staining, the remaining serial sections were used for IHC. This study was carried out in double blinded fashion.

### Immunohistochemistry

Immunohistochemistry (IHC) was performed on tissue sections as described previously [21]. Briefly, paraffin sections were first deparaffinized and microwaved in sodium-citrate buffer (pH 6.0) for antigen retrieval. After endogenous peroxidase inactivation, sections were incubated with 10% preimmune serum. Sections were further incubated with primary mouse monoclonal antibodies- anti-cytokeratin 1-clone 34βB4, and anti-cytokeratin 5-clone XM26, (Novocastra Laboratories Ltd, Newcastle, UK) at dilutions 1:40 and 1:200, respectively. Anti-cytokeratin 8-clone M20, and anti-cytokeratin 18-clone CY90, (Sigma, Missouri 63103, USA) both at dilutions 1:200 followed with an Avidin-Biotin-Peroxidase complex kit (Vector Laboratories, CA 94010, USA). Serum from non-immunized mouse was used as negative control. Human epidermal sections for K1 and K5 and liver sections for K8 and K18 immunolabeling were used as positive controls. The expression of K1, K5, K8 and K18 in IHC staining was quantified by visual assessment under the microscopic field at x200 magnification by counting a total of 100 cells per field and for each section total three fields were counted by two independent observers. Immunoreactivity

was divided into four categories and defined as: <10% (-/no), 11–30% (+/low), 31–50% (++/moderate) and >51% (+++/intense). Immunolabeling specificity of all primary antibodies used in this study was also tested on cryostat sections to rule out the possibility of artifact formation due to formalin fixation.

### Statistical analysis

Univariate analysis was performed to determine the correlation of clinicopathological parameters with expression profile of keratin markers using Pearson chi-square test. For survival analysis, overall survival was defined as time from surgery until death as a result of any cause and recurrence free survival was defined as time from surgery until tumor recurrence or death due to disease. Survival curves for overall survival and recurrence free survival were constructed using Kaplan–Meier method and differences between curves were compared using Log Rank test [22]. Univariate and multivariate analysis for overall survival and recurrence free survival was carried out using Cox Proportional Hazards model to identify factors predicting survival [15]. Considering the variable to event ratio, the factors which showed significance ( $p < 0.2$ ) in univariate analysis were considered for multivariate analysis in both overall survival and for recurrence free survival. Clinicopathological variables such as tumor stage (T1, T2, T3 and T4), nodal metastasis (yes/no), perineural invasion (positive/negative),

tumor site (tongue/buccal mucosa) were considered as categorical variables. In Cox regression analysis variables like K1, K5, K8 and K18 were dichotomized as ‘+’ and ‘-’. The combinations of markers K1, K8 and K18 were considered for Cox regression analysis. The combinations were classified as “All negative”, “Any one positive”, “Any two positive” and “All positive”. Data was analyzed using SPSS software, version 21.0 (SPSS Inc., Chicago, IL, USA). Differences with a probability value of <0.05 were considered statistically significant.

### RESULTS

This study comprises immunohistochemical analysis of loss of K5 expression and aberrant expression of K1, K8 and K18 in the tissues with oral mucosal hyperplasia/dysplasia, fibrosis and SCC (tongue and BM) along with their respective cut margin (CM) tissues in comparison with normal oral mucosal tissues. Clinicopathological information of patients with leukoplakia and SMF and their correlation with keratin expression profile is given in Table 1. Clinicopathological information of patients with OSCC is given in Table 2.

Histopathology of H&E stained sections of normal oral mucosa, mucosal hyperplasia, dysplasia, fibrosis, tongue SCC, cut margins of tongue tumors, buccal mucosal SCC and cut margins of buccal mucosal tumors is shown in Figure 1A–H.

Table 1: Correlation between K5 non expression, K1, K8 and K18 expression and clinicopathological parameters of patients with buccal mucosal leukoplakia, submucous fibrosis and normal buccal mucosa

Precancerous Lesions / Variable		Total Cases	Keratin1 Positive Number (%)	P Values	Keratin5 Negative Number (%)	P Values	Keratin8 Positive Number (%)	P Values	Keratin18 Positive Number (%)	P Values
<b>Leukoplakia n=52</b>	Age: median 38.5 (range 18–70 years), Gender: Male 48, Female 4									
Types	Non-homogenous	18	14 (78)	<0.001	6 (33)	0.015	14 (78)	<0.001	15 (85)	<0.001
	Homogenous	34	6 (18)		2 (5)		6 (18)		8 (24)	
Dysplastic Grade:	Hyperplasia	31	3 (10)	<0.001	1 (3)	0.003	5 (16)	0.001	8 (26)	0.004
	Mild Dysplasia	11	9 (82)		2 (18)		7 (64)		6 (55)	
	Moderate Dysplasia	7	5 (71)		3 (42)		5 (71)		6 (86)	
	Severe Dysplasia	3	3 (100)		2 (66)		3 (100)		3 (100)	
<b>SMF n=67</b>	Age: Median 44.0 (range 18–72 years). Gender: Male 44, Female 23									
Fibrosis Grade:	Mild Fibrosis	14	5 (36)	0.58	1 (7)	0.273	2 (14)	0.086	2 (14)	0.011
	Moderate Fibrosis	34	14 (41)		5 (14)		6 (18)		6 (18)	
	Severe Fibrosis	19	10 (53)		3 (15)		8 (42)		10 (53)	
<b>Normal tissue</b>	Buccal Mucosa	10	0		0	-	0	-	0	-

Bold values signify  $p$ -value <0.05. Applied Pearson chi-square test.

Table 2: Correlation of K 5 non-expression, K1, K8 and Ki8 expression with clinico-pathological parameters of the patients with oral squamous cell carcinoma

Clinico-pathological parameters N=304	Subcharacteristics	Keratin 1 Expression			Keratin 5 Expression			Keratin 8 Expression			Keratin 18 Expression				
		Low		High	Positive		Negative	Low		Moderate	High	Low		Moderate	High
Tumor Site	Tongue	41	25	15	132	12	12	55	26	10	25	51	13	0.39	
	BM	53	20	12	143	17	17	60	26	7	35	46	12	0.31	
Tumor Thickness	<2cm	70	34	21	214	25	25	86	43	16	52	75	19	0.42	
	≥2cm	24	11	6	63	4	4	29	9	1	9	22	6	0.34	
Clinical tumor Stage	I	4	2	1	15	2	2	7	2	1	4	4	2		
	II	9	7	1	33	4	4	17	4	2	10	7	2	0.034	
	III	16	5	6	51	2	2	18	6	2	16	14	1	0.77	
	IV	65	31	19	178	21	21	73	40	12	31	72	20	0.48	
Tumor Size	T1	5	2	2	18	3	3	8	2	1	4	6	1		
	T2	26	18	5	91	10	10	38	13	5	25	29	7	0.76	
	T3	12	3	6	41	2	2	15	7	2	7	14	5	0.61	
	T4	51	22	14	127	14	14	54	30	9	25	48	12	0.36	
Nodal metastasis	NO	35	12	8	99	15	15	47	18	4	29	27	7		
	N1	26	8	7	69	3	3	26	11	6	16	21	6	0.12	
	N2	33	25	12	109	11	11	42	23	7	16	49	12	0.24	
Histological Grade	Well	12	4	3	31	3	3	16	6	1	8	13	2		
	Moderate	53	28	17	170	14	14	70	32	12	33	58	14	0.28	
	Poor	29	13	7	76	12	12	29	14	4	20	26	9	0.93	
Bone Involvement	Positive	28	9	8	60	6	6	24	10	3	12	18	5	0.81	
	Negative	36	23	13	140	17	17	53	31	10	31	48	12	0.33	
Lymphovascular Invasion	Yes	2	1	2	11	0	0	5	5	0	3	4	1	0.42	
	No	76	40	24	230	26	26	98	39	12	50	81	19	0.60	
Perineural Invasion	Yes	45	22	15	124	12	12	50	24	9	22	49	15	0.93	
	No	39	18	11	122	13	13	54	21	6	26	43	7	0.42	
Skin Involvement	Yes	13	2	0	24	2	2	10	5	0	6	9	1	0.016	
	No	39	26	17	128	17	17	52	24	9	24	47	14	0.74	

Values highlighted represent statistically significant p-value (p<0.05); Pearson chi-square / Fisher's Exact Test applied wherever applicable.




Figure 1: (A–H): Representative images of Hematoxylin- and Eosin-stained tissue sections of (A) Normal buccal mucosa, (B) Hyperplastic buccal mucosa (C) Dysplastic buccal mucosa, (D) Fibrotic buccal mucosa, (E) Squamous cell carcinoma of tongue, and (F) Cut margin of the same tumor, (G) Squamous cell carcinoma of buccal mucosa, (H) Cut margin of the same tumor. (Magnification, A–H, x200). All images taken on Zeiss Microscope Axio Imager-Z1, Germany.

## Immunohistochemical analysis of alterations in K1, K5, K8 and K18 expression

### Keratin 5 non-expression

K5 expression was seen in the epithelium of all normal oral mucosal tissues. Immunolabeling was detected in the cytoplasm of basal and suprabasal epithelial layers but not in the uppermost stratified layer. Staining intensity was high in basal layer and it was reduced in the suprabasal layers (Figure 2A:a). Although, K5 is a normal expression in the basal layer of all stratified epithelia, loss of K5 expression was seen in some of the hyperplastic/dysplastic and fibrotic

tissues. Leukoplakia samples were sub-grouped into non-homogeneous and homogeneous leukoplakia on the basis of clinical observations. Thirty-three percent of non-homogeneous as against 6% of homogeneous leukoplakia samples did not show detectable amount of K5 expression ( $p=0.015$ ) (Figure 2B). Leukoplakia samples were further sub-grouped into hyperplasia, mild, moderate and severe dysplasia, and SMF samples into mild, moderate and severe fibrosis on the basis of histopathological diagnosis. Loss of K5 was detected in 15% of hyperplastic/dysplastic samples and 13% of fibrotic samples (Figure 2C). Percentage of samples with loss of K5 expression increased in both leukoplakia as well as SMF as the histopathological grade of the




Figure 2: (A) Alterations in keratin 5 expression were examined by immunohistochemistry in oral tissue sections. (a) Staining shown in the basal and suprabasal normal oral buccal mucosal epithelium, (b) Very low expression in the suprabasal hyperplastic epithelium, (c) No expression in dysplastic epithelium, (d) No expression in fibrotic epithelium, (e) Very weak expression in the epithelium of tongue tumor, (f) Very weak expression in the suprabasal epithelial cells of the cut margin of same tumor, (g) Moderate expression in the epithelium of buccal mucosa tumor, (h) Weak to moderate expression in the suprabasal epithelial cells of cut margin of the same tumor. (Magnification a–h 200X).

Figure 2 (B): Graphical representation of percentage samples showing significant correlation between loss of keratin 5 expression and non-homogeneous versus homogeneous leukoplakia ( $p=0.015$ ). Results are mean  $\pm$  s.e. (C): Graphical representation of percent samples showing loss of K5 expression in oral mucosal epithelium of normal, hyperplastic, dysplastic, fibrotic, squamous cell carcinoma of tongue, cut margin of tongue, squamous cell carcinoma of buccal mucosa, cut margin of buccal mucosa tissues. (D): Graphical representation of staining intensity in keratin 5 positive samples of oral mucosal epithelium from normal, hyperplastic, dysplastic, fibrotic, squamous cell carcinoma of tongue, cut margin of tongue, squamous cell carcinoma of buccal mucosa, cut margin of buccal mucosa tissues. Results are mean  $\pm$  s.e. (E): Graphical representation of percent samples showing correlation between loss of K5 expression in tumor ( $p=0.037$ ) and cut margin ( $p=0.410$ ) tissues and development of local recurrence. Results are mean  $\pm$  s.e.

disease increased (Table 1). However, significant correlation was observed only with progressive grade of dysplasia ( $p=0.003$ ) and not with fibrosis (Table 1).

K5 expression was not detected in 8% of tongue and 11% of BM tumor tissues (Figure 2C). Their respective cut margin tissues also showed non-expression of K5 in 12% of tongue and 11% of BM tissues, respectively (Figure 2C). Different patterns of K5 immunolocalization in comparison with normal mucosal tissues were seen in hyperplastic/dysplastic, fibrotic as well as SCC tissues studied. Those types are i) Weak overall staining intensity for K5. ii) Loss of K5 staining in the basal and immediate suprabasal cell layers. iii) Loss of K5 staining in all the epithelial cell layers (Figure 2A:a–h). The staining intensity of K5 positive samples varied from sample to sample and sometimes even in the same tissue section, different cells stained with different intensity (Figure 2A:e–f, Figure 2D). K5 non-expression in tumor tissues significantly correlated with tumor site ( $p=0.023$ ), nodal metastasis ( $p=0.029$ ), and local recurrence ( $p=0.037$ ), (Table 2, Figure 2E). Although K5 expression in tumor tissues significantly correlated with nodal metastasis, its immunostaining was not detected in the lymphatic cells of either nodal metastatic or non-metastatic tumors (Figure 3:a, b).

### Keratin 1 expression

K1 expression was non-detectable in normal buccal mucosal epithelium (Figure 4A:a). However, its cytoplasmic localization was seen in hyperplastic/dysplastic, fibrotic and cancerous epithelial tissues. Localization was mainly restricted in the differentiated epithelia and proliferative basal cells were not immunostained (Figure 4A: a–h). K1 expression was seen in 78% of non-homogeneous as against 18% of homogeneous leukoplakia samples ( $p<0.001$ ) (Figure 4B). Further, 38% of hyperplasia/dysplasia and 27% of fibrosis samples demonstrated K1 expression (Figure 4C). The percentage of samples expressing K1 increased as the histopathological grade of the disease progressed in both leukoplakia and SMF but it is significantly correlated only with leukoplakia samples ( $p<0.001$ ) (Table 1).

Detectable levels of K1 expression were also seen in 81/144 (56%) of tongue tumors and 143/160 (89%) of BM tumors while respective cut margin tissues of tongue 132/144 (92%) and BM 85/160 (53%) showed K1 immunolabeling (Figure 4C). Moderate intensity of K1 staining was seen in majority of samples while few samples also showed weak to intense staining (Figure 4D). K1 expression in tumor tissues significantly correlated with tumor size ( $p=0.030$ ), nodal metastasis ( $p=0.040$ ), bone involvement ( $p=0.007$ ), skin involvement ( $p=0.040$ ), and development of local recurrence ( $p=0.001$ ) (Table 2, Figure 4E), while in cut margin tissues it correlated with tumor site ( $p=0.001$ ), nodal metastasis ( $p=0.002$ ), and perineural invasion ( $p=0.022$ ). (Table 3, Figure 4E).

Immunolabeling for K1 was not detected in the lymphatic cells of nodal metastatic or non-metastatic tumors (Figure 3:c, d).

### Keratin 8 expression

Simple epithelia specific K8 expression was not detectable in normal stratified buccal mucosal epithelium (Figure 5A:a) but its immunoreactivity was seen in hyperplastic/dysplastic, fibrotic and cancerous epithelial tissues. Cytoplasmic localization was detected in the suprabasal epithelial cells of majority of tissues while few tissues also showed immunolabeling in the basal cell layer (Figure 5A:a–h). K8 expression was observed in 78% of non-homogeneous as against 18% of homogeneous leukoplakia samples ( $p<0.001$ ) (Figure 5B). Significant correlation between K8 positive samples and the progressive grade of dysplasia was found in these samples ( $p=0.001$ ) (Table 1).

Detectable level of K8 expression was also seen in 90/144 (63%) of tongue and 91/160 (59%) of BM tumors while their respective cut margin tissues showed K8 labeling in 84/144 (57%) of tongue tissues and 76/160 (48%) of BM tissues (Figure 5C). Overall staining intensity for K8 was weak to moderate although few samples also showed intense labeling (Figure 5D). K8 expression in tumor tissues significantly correlated with tumor size ( $p=0.042$ ), lymphovascular invasion ( $p=0.023$ ) and local recurrence ( $p=0.001$ ) (Table 2, Figure 5E). Its expression in cut margin tissues also significantly correlated with lymphovascular invasion ( $p=0.024$ ) and local recurrence ( $p=0.001$ ) (Table 3, Figure 5E). It is a well-known fact that many times localization of protein can determine its function and thus may be of clinical importance. Hence, we analyzed K8 immunolabeling in the invasive front of tumor cells. K8 immunolabeling was seen in the cells at tumor fronts of 70/181 (37%) invasive tumors (Figure 6A). Out of those 70 patients whose tumor invasive fronts were positive, 59 (84%) patients eventually developed recurrence (Figure 6B). Although, K8 immunolabeling was positive in tumor cells of nodal metastatic/non-metastatic SCC, it was not detected in the lymph nodes of same tumors (Figure 3:e,f).

### Keratin 18 expression

Although, K18 immunolocalization was not demonstrated in normal BM epithelium (Figure 7A:a) it was seen in hyperplastic/dysplastic, fibrotic and cancerous tissues. K18 staining was mainly restricted to the cytoplasm of suprabasal epithelial cells and in few samples it was also seen in the basal layer cells (Figure 5A:a–h). Eighty-five percent of non-homogeneous and 24% of homogeneous leukoplakia samples showed significant levels of K18 expression ( $p<0.001$ ) (Figure 7B). Like K8 expression, K18 expression not only significantly






Figure 3: Immunostaining showing positive labeling in the primary tumors but no labeling in their respective lymph nodes (A) K5 labeling in tumor and (B) in lymph node. (C) K1 labeling in tumor and (D) in lymph node. (E) K8 labeling in tumor and (F) in lymph node. (G) K18 labeling in tumor and (H) in lymph node. Magnification, A-H, x200.

correlated with the progressive grade of dysplasia ( $p=0.004$ ) but also with fibrosis ( $p=0.011$ ) (Table 1).

K18 immunostaining was found in 89/144 (62%) of tongue tumors and 93/160 (58%) of BM tumors while, their respective cut margin tissues showed K18 labeling in 81/144 (56%) of tongue tissues and 70/160 (44%) of BM tissues (Figure 7C). The overall staining intensity of K18 was moderate although few samples also demonstrated weak or intense labeling (Figure 7D). It is known that K8 and K18 are pairing partners, but in some of the tissues the immunolabeling for both K8 and K18 in the serial sections of the same tissue was not observed (Figure 5A: a, b, d, f, h and Figure 7A: a, b, d, f, h). K18

expression in tumor tissues significantly correlated with tumor stage ( $p=0.028$ ), nodal metastasis ( $p=0.013$ ), and local recurrence ( $p=0.001$ ) (Table 2, Figure 7E) while, in cut margin tissues its expression significantly correlated with development of local recurrence ( $p=0.001$ ) (Figure 7E). K18 immunolabeling was seen in the invasive front of 81 tumor samples (Figure 6C). Out of these, 63 (78%) patients eventually developed recurrent tumor (Figure 6D). Although, K18 expression significantly correlated with nodal metastasis, it was not detected in the lymph nodes of the metastatic/non-metastatic tumor sections (Figure 3: g,h).




Figure 4: (A) Keratin 1 expression was examined by immunohistochemistry on oral tissue sections. (a) Negative expression of K1 in normal buccal mucosal epithelium, (b) No detectable labeling in the basal and immediate suprabasal layer cells but positive labeling in the suprabasal cells of hyperplastic epithelium, (c) Very weak labeling in the suprabasal cells of dysplastic epithelium, (d) Intense labeling was noted in the differentiated suprabasal cells of fibrotic epithelium. (e) Intense immunolabeling in the epithelium of tongue tumor. (f) Strong positive labeling in the suprabasal epithelial cells with varied staining intensity from cell to cell in the cut margin tissue of tongue. (g) Strong labeling with varied staining intensity in the epithelium of BM tumor, (h) Strong labeling in the suprabasal epithelial cells of BM cut margin. (Magnification a–h x200).

Figure 3 (B): Graphical representation of percentage samples showing significant correlation between expression of K1 and non-homogeneous versus homogeneous leukoplakia ( $p<0.001$ ). Results are mean  $\pm$  s.e. (C): Graphical representation of percent samples showing expression of K1 in oral buccal mucosal epithelium of normal, hyperplastic, dysplastic, fibrotic, SCC of tongue, cut margin of tongue, SCC of BM, cut margin of BM tissues. (D): Graphical representation showing staining intensity in K1 positive samples of buccal mucosal epithelium from normal, hyperplastic, dysplastic, fibrotic, SCC of tongue, cut margin of the same tumor, SCC of BM, cut margin of the same tumor. Results are mean  $\pm$  s.e. (E): Graph representing significant correlation between percent samples expressing K1 in tumor ( $p=0.001$ ) and cut margin tissues ( $p=0.021$ ) and development of local recurrence. Results are mean  $\pm$  s.e.




Figure 5 (A): Keratin 8 expression was examined by immunohistochemistry on oral tissue sections, (a) Non expression of K8 in normal buccal mucosal epithelium, (b) Weak labeling in the suprabasal cells and no labeling in the basal cells of hyperplastic epithelium, (c) Intense labeling in the suprabasal cells of dysplastic epithelium, (d) Intense staining in the suprabasal cells of fibrotic epithelium, (e) Intense immunolabeling in the epithelium of tongue tumor, (f) Weak to moderate staining in the suprabasal epithelium of cut margin of the same tumor, (g) Strong labeling with homogeneous staining intensity in the epithelium of BM tumor, (h) Strong labeling in the basal as well as suprabasal cells of cut margin of the same tumor. (Magnification a–h x200).

Figure 4 (B): Graphical representation of percentage samples showing significant correlation between expression of K8 and non-homogeneous versus homogeneous leukoplakia ( $p < 0.001$ ). Results are mean  $\pm$  s.e. (C): Graphical representation of percent samples showing expression of K8 in buccal mucosal epithelium of normal, hyperplastic, dysplastic, fibrotic, SCC of tongue, cut margin of tongue, SCC of BM, cut margin of BM tissues. (D): Graph showing staining intensity in K8 positive samples of buccal mucosal epithelium from normal, hyperplastic, dysplastic, fibrotic, SCC of tongue, cut margin of tongue, SCC of BM, cut margin of BM tissues. Results are mean  $\pm$  s.e. (E): Graph representing significant correlation between percent samples expressing K8 in tumor ( $p = 0.001$ ) and cut margin ( $p = 0.001$ ) tissues and development of local recurrence. Results are mean  $\pm$  s.e.

### Correlation between altered keratin expression pattern and survival of oral cancer patients: univariate and multivariate analysis

To further investigate the prognostic value of these keratin proteins in patients with oral cancer, we performed univariate analysis with different combinations of keratin markers and patient's clinical parameters as given in Table 4. Parameters which showed statistically significant  $p$ -values in univariate analysis were further evaluated by multivariate Cox

regression analysis to estimate the time of survival and to predict the development of local recurrence in patients with OSCC. Tumor site, tumor stage, nodal metastasis, and perineural invasion, along with different combinations of K1, K8 and K18 significantly correlated with overall survival (Table 5), as well as with the local recurrence (Table 6). Kaplan–Meier survival analysis with the different combinations of aberrantly expressed keratin markers (K1, K8, and K18) showed significant correlation with overall survival as well as with recurrence free survival of patients with tongue and buccal mucosal cancer as shown in Figure 8.

**DISCUSSION**

Keratins are epithelia-predominant intermediate filament proteins, which are expressed in a tissue-specific and paired manner [23]. However, alterations in their normal expression pattern have been shown in different pathological disorders, such as, gingivitis, psoriasis, and hyperkeratosis [24, 25]. Alterations have also been shown in leukoplakia, oral submucous fibrosis (OSMF), and OSCC [26, 27].

In this study, immunohistochemistry was carried out to localize and semi-quantitate the expression of K1, K5, K8 and K18 in normal oral mucosa, oral epithelial

hyperplasia/dysplasia, OSMF and OSCC tissues. The results of the IHC analysis were correlated with clinicopathological parameters of respective patients. In this study, we have made an attempt to cover major histopathological stages occurring during the process of oral tumor development. This study also covers two major sub-sites of the oral cavity that is tongue and BM which are the most prevalent sub-sites for the development of tumor in Indian patients due to the typical habits of chewing tobacco and allied products. These two sub-sites not only vary in their anatomical location and function but also show different pattern of keratin expression. The percentage of positivity and staining intensity of keratin




Figure 6: (A) Immunostaining for K8 in tumor invasive cells (Magnification, x200), (B) Histogram illustrating correlation between K8 positivity at invasive front of the tumor and development of local recurrence, (C) Tumor invading cells showing K18 positive immunolabeling (Magnification x200), (D) Histogram illustrating correlation between K18 positivity at invasive front of the tumor and development of local recurrence.

Table 3: Correlation between K5 non-expression, K1, K8 and K18 expression in cut margin tissues and clinicopathological parameters of the patients with oral squamous cell carcinoma (OSCC)

Clinico-pathological parameters N=304	Keratin 1 Expression			Keratin 5 Expression			Keratin 8 Expression			Keratin 18 Expression			
	Low	Moderate	High	Positive	Negative	p-value	Low	Moderate	High	Low	Moderate	High	p-value
<b>Tumor Site</b>													
<b>Tongue</b>	30	75	27	127	17	0.095	61	20	3	47	26	8	0.62
<b>BM</b>	49	72	22	143	17		49	25	3	41	25	4	0.45
<b>Tumor Thickness</b>													
<b>&lt;2cm</b>	66	118	32	215	24	0.038	88	36	3	70	45	8	0.21
<b>≥2cm</b>	13	29	17	57	10		22	9	3	18	6	4	0.17
<b>Clinical Stage</b>													
<b>I</b>	4	9	2	17	10		7	1	0	3	2	1	
<b>II</b>	14	16	3	32	15	0.36	17	3	1	11	7	1	0.91
<b>III</b>	16	22	11	49	4		18	7	1	13	10	1	
<b>IV</b>	45	100	33	174	25		68	34	4	61	32	9	
<b>Tumor Size</b>													
<b>T1</b>	3	9	4	20	1	0.69	6	0	1	3	2	2	0.22
<b>T2</b>	31	50	13	88	13		36	14	3	31	16	5	0.16
<b>T3</b>	10	24	6	40	3		16	4	1	7	10	1	
<b>T4</b>	35	64	26	124	17		52	27	1	47	23	4	
<b>Nodal metastasis</b>													
<b>NO</b>	39	43	15	97	17	0.14	48	15	1	35	15	4	0.46
<b>N1</b>	17	36	14	68	4	0.031	27	15	1	18	13	4	0.67
<b>N2</b>	23	68	20	107	13		41	15	4	35	23	4	
<b>Histological Grade</b>													
<b>Well</b>	14	11	8	73	15	0.15	11	5	1	14	3	0	0.965
<b>Moderate</b>	46	93	26	168	16		68	26	3	51	33	9	
<b>Poor</b>	19	43	15	31	13		31	14	2	23	15	3	
<b>Bone Involvement</b>													
<b>Positive</b>	21	30	7	58	8	0.33	22	11	0	17	10	2	0.63
<b>Negative</b>	40	73	28	142	15		57	20	4	41	26	4	0.31
<b>Lymphovascular Invasion</b>													
<b>Yes</b>	1	7	2	11	0	0.36	6	4	0	5	2	0	0.49
<b>No</b>	69	116	43	224	32		9	32	6	69	44	9	
<b>Perineural Invasion</b>													
<b>Yes</b>	26	73	27	121	15	0.030	48	20	4	40	21	5	0.70
<b>No</b>	42	55	20	121	14		50	19	2	37	27	6	0.66
<b>Skin Involvement</b>													
<b>Yes</b>	8	10	3	24	2	0.77	6	5	0	5	5	1	0.20
<b>No</b>	40	66	24	130	15		56	16	3	34	28	7	0.95

Values highlighted represent statistically significant p-value (p<0.05); Pearson chi-square / Fisher's Exact Test applied wherever applicable.

Table 4: Univariate analysis correlating clinical parameters of oral squamous cell carcinoma (OSCC) patients and alterations in keratin expression pattern in Overall Survival and Recurrence Free Survival, evaluating hazard ratio, confidence interval and p-values.

Characteristics	Sub-Characteristics		No. of Cases		Overall survival		Recurrence free survival	
	Hazard ratio	95% Confidence Interval	Hazard ratio	95% Confidence Interval	p-values	Hazard ratio	95% Confidence Interval	p-values
Age	<50 Years	-	174	-	-	-	-	-
	≥50 Years	1.07	132	0.73-1.59	0.71	0.80	0.52-1.22	0.30
Gender	Female	-	66	-	-	-	-	-
	Male	1.16	240	0.71-1.89	0.55	1.11	0.66-1.86	0.70
Tumor Site	BM	-	160	-	-	-	-	-
	Tongue	1.64	144	1.11-2.43	<b>0.013</b>	1.72	1.14-2.6	0.010
Tumor thickness	<2cm	-	239	-	-	-	-	-
	≥2cm	0.97	67	0.61-1.56	0.92	1.12	0.69-1.81	0.66
Clinical stage	I	-	17	-	-	-	-	-
	II	1.09	37	0.33-3.64	0.88	0.866	0.31-2.4	0.78
	III	1.88	53	0.65-5.49	0.25	0.721	0.27-1.93	0.52
	IV	1.70	199	0.62-4.66	0.30	0.999	0.43-2.32	1.0
Tumor Stage	T1	-	21	-	-	-	-	-
	T2	2.44	101	0.75-8.01	0.14	3.85	0.92-16.15	0.07
	T3	4.46	43	1.33-14.97	<b>0.016</b>	4.87	1.1-21.55	0.037
	T4	2.89	141	0.90-9.30	0.073	3.92	0.95-16.2	0.06
Nodal metastasis	No	-	114	-	-	-	-	-
	Yes	0.67	192	0.44-1.03	0.066	0.56	0.36-0.90	0.016
Histological grade	Well	-	34	-	-	-	-	-
	Moderate	1.23	184	0.61-2.49	0.57	1.10	0.54-2.22	1.10
	Poor	1.44	88	0.69-3.03	0.33	1.35	0.64-2.86	1.35
Bone Involvement	Negative	-	157	-	-	-	-	-
	Positive	0.90	66	0.54-1.51	0.70	1.04	0.61-1.78	0.88

Table 4: (Continued)

Characteristics	Sub-Characteristics	No. of Cases	Overall survival		Recurrence free survival			
			Hazard ratio	95% Confidence Interval	Hazard ratio	95% Confidence Interval	p-values	
<b>Lymphatic Invasion</b>	Negative	256						
	Positive	11	1.77	0.72-4.38	0.21	1.77	0.65-4.86	0.27
<b>Perineural Invasion</b>	Negative	211	-	-	-	-	-	-
	Positive	65	1.65	1.05-2.58	0.029	1.80	1.12-2.89	0.015
<b>Skin Involvement</b>	No	145	-	-	-	-	-	-
	Yes	26	1.46	0.74-2.91	0.28	1.32	0.59-2.96	0.50
<b>K1, K8, K18 Combinations</b>	All Negative	54	-	-	-	-	-	-
	Any 1 Positive	71	2.89	1.24-6.71	0.014	2.19	0.43-11.33	0.35
	Any 2 Positive	81	4.209	1.85-9.59	0.001	11.52	2.71-48.89	0.001
	All Positive	100	4.34	1.94-9.73	<0.001	24.06	5.86-98.71	<0.001
<b>K5</b>	Positive	277	-	-	-	-	-	-
	Negative	29	0.85	0.44-1.65	0.63	1.02	0.53-1.98	0.95

Bold values represent significant p-values ( $p < 0.05$ ).

Table 5: Multivariate analysis (Overall Survival) for expression of keratin markers and clinical parameters of patients with oral squamous cell carcinoma (OSCC)

Prognostic Factors		Relative Risk Lower	95 % Confidence Interval Upper		p-value
<b>Tumor Stage</b>	T1	-	-	-	-
	T2	3.77	0.88	16.09	0.073
	T3	7.20	1.67	31.52	<b>0.009</b>
	T4	5.51	1.31	23.22	<b>0.020</b>
<b>Nodal Metastasis</b>	No	-	-	-	-
	Yes	1.38	0.85	2.24	0.189
<b>Perineural Invasion</b>	No	-	-	-	-
	Yes	1.20	0.73	1.98	0.467
<b>Tumor Site</b>	Buccal mucosa	-	-	-	-
	Tongue	1.83	1.17	2.86	<b>0.008</b>
<b>K1,K8,K18</b>	All Negative	-	-	-	-
	Any One Positive	3.19	1.19	8.5	<b>0.021</b>
	Any Two Positive	4.24	1.61	11.16	<b>0.003</b>
	All Positive	3.95	1.53	10.21	<b>0.005</b>

Bold values represent significant p-values ( $p < 0.05$ ).

Table 6: Multivariate analysis (Recurrence free survival) for expression of Keratin markers and Clinical parameters in patients with oral squamous cell carcinoma (OSCC)

Prognostic Factors		Relative Risk Lower	95 % Confidence Interval Upper		p-value
<b>Tumor Stage</b>	T1	-	-	-	-
	T2	9.99	1.33	75.20	<b>0.025</b>
	T3	11.89	1.52	93.08	<b>0.018</b>
	T4	8.31	1.12	61.75	<b>0.038</b>
<b>Nodal Metastasis</b>	No	-	-	-	-
	Yes	1.33	0.78	2.25	0.30
<b>Perineural Invasion</b>	No	-	-	-	-
	Yes	1.22	0.74	2.01	0.445
<b>Tumor Site</b>	Buccal mucosa	-	-	-	-
	Tongue	1.63	1.02	2.59	<b>0.04</b>
<b>K1,K8,K18</b>	All Negative	-	-	-	-
	Any One Positive	1.72	0.31	9.46	0.531
	Any Two Positive	9.53	2.22	40.96	<b>0.002</b>
	All Positive	19.72	4.75	81.98	<b>&lt;0.001</b>
	Ptrend	<0.0001			

Bold values represent significant p-values ( $p < 0.05$ ).



expression was high for tongue tissues as compared to buccal mucosa. Overall survival rate for three years (52.3%) and five years (22.9%) in patients with tongue cancer was poorer as compared to patients with buccal mucosal cancer (66.8% and 66.8%, respectively). Also, it is general clinical observation that tongue tumors are more aggressive than the buccal mucosal tumors. Hence, we evaluated the significance of aberrantly expressed K1, K8 and K18 in different combinations with overall survival and recurrence free survival separately in subset of patients with tongue and buccal mucosal cancer. Interestingly, combinations of different keratin markers

expressed by these sub-sites significantly correlated with overall survival as well as recurrence free survival.

The expression of keratin pair 5/14 is a hallmark of squamous epithelium and is predominantly seen in the basal layers of stratified epithelium. This cell layer is mainly composed of tissue specific stem/progenitor cells. Stem cells of stratified epithelium have been described as the major cellular targets for cancer causing mutations and therefore might give in a long-term rise to the development of cancer. In this context, although K5 is a normal expression in oral cavity, it is interesting to evaluate the clinical significance of alterations in its




Figure 7 (A): Keratin 18 expression was examined by immunohistochemistry on oral tissue sections. (a) Non expression of K18 in normal oral mucosal epithelium, (b) Moderate staining in the suprabasal cells and no staining in the basal cells of hyperplastic epithelium, (c) Moderate staining in the suprabasal cells of dysplastic epithelium, (d) Moderate staining in the suprabasal cells of fibrotic epithelium, (e) Intense immunolabeling in the epithelium of tongue tumor, (f) Moderate to intense heterogeneous staining in the suprabasal epithelium of cut margin of the same tumor, (g) Strong expression with homogeneous staining intensity in the epithelium of buccal mucosa tumor, (h) Weak staining in the suprabasal cells of cut margin of the same tumor (Magnification, a-h x200).

Figure 7 (B): Graphical representation of percentage samples showing significant correlation between expression of K18 and non-homogeneous versus homogeneous leukoplakia ( $p < 0.001$ ). Results are mean  $\pm$  s.e. (C): Graphical representation of percent samples showing expression of K18 in oral mucosal epithelium of normal, hyperplastic, dysplastic, fibrotic, squamous cell carcinoma of tongue, cut margin of tongue, squamous cell carcinoma of buccal mucosa, cut margin of buccal mucosa tissues. (D): Graph showing staining intensity in K18 positive samples of buccal mucosal epithelium from normal, hyperplastic, dysplastic, fibrotic, squamous cell carcinoma of tongue, cut margin of tongue, squamous cell carcinoma of buccal mucosa, cut margin of buccal mucosa tissues. Results are mean  $\pm$  s.e. (E): Graph representing significant correlation between percent samples expressing K18 in tumor ( $p = 0.001$ ) and cut margin ( $p = 0.001$ ) tissues and development of local recurrence. Results are mean  $\pm$  s.e.




Figure 8: Kaplan–Meier survival curves showing overall survival and recurrence free survival in patients with tongue and buccal mucosal cancer. (A, B): Showing the overall survival for patients with tongue ( $p=0.049$ ) and buccal mucosal ( $p=0.004$ ) cancer according to the combination of Keratin markers (K1, K8 and K18), (C, D) Showing the recurrence free survival for patients with tongue ( $p<0.0001$ ) and buccal mucosal ( $p=0.0001$ ) cancer according to the combination of keratin markers (K1, K8 and K18).

expression pattern. In this study, we have observed different patterns of K5 immunolocalization in both premalignant SCC tissues as shown in results (Figure 2A: a–h). Previously, we have shown loss of K5 at protein [18–20] as well as RNA level [14] in oral premalignant lesions including in OSCC. We have also reported the role of K5/14 in regulation of cell differentiation/proliferation [28]. This keratin pair is known to negatively regulate cell differentiation. Thus it is possible that loss of K5 may induce changes which lead to abnormal cell differentiation.

Other than us, only Morgen and Su [29] have shown loss of K5 expression in human oral dysplasia and SCC. Although, they have shown down regulation of K5 and K14 in some poorly differentiated SCC of oral cavity tissues, we have seen loss of K5 in all grades of SCC including hyperplasia and dysplasia. In this study, the immunoreactivity of all primary antibodies was tested on relevant frozen tissues to rule out the possibility of

detection of artifacts due to formalin fixation.

Further, we have correlated the non-expression of K5 with clinicopathological parameters of patients with precancerous lesions as well as SCC. K5 non-expression was seen in significantly higher number of non-homogenous leukoplakia samples as compared to homogeneous leukoplakia samples. Non-expression of K5 also significantly correlated with progressive grade of dysplasia. It is known that in Indian patients, the typical habits of chewing tobacco/areca nut and other ingredients contribute to the pathogenesis of leukoplakia and SMF [17, 30, 31]. Majority of the subjects recruited in this study had habits of chewing tobacco/areca nut along with other multiple habits. Thus K5 non-expression appears to be an early change occurring in the process of tobacco related oral carcinogenesis.

Keratin pair of 1/10 is known to be a marker of cellular differentiation, and many well-differentiated SCCs derived from non-keratinizing stratified epithelia

also express this keratin pair [18, 26]. In this study, cytoplasmic K1 expression has been detected in the intermediary cell layers of hyperplastic/dysplastic, fibrotic tissues as well as tumor tissues. The intermediary cells are usually comprised differentiated cell population. None of the sample showed K1 staining in the basal layer which is usually a proliferating cell population. K1 expression significantly correlated with some of the clinicopathological parameters of patients. For example, K1 aberrant expression was seen in significantly higher number of non-homogenous buccal leukoplakia samples as compared to homogeneous leukoplakia samples. It has been reported that non-homogenous leukoplakia is more prone for malignant conversion over a period of time as compared to homogenous leukoplakia [32]. A recent report on large-scale follow-up study also showed high risk of malignant transformation in patients who had non-homogenous leukoplakic lesions with high-grade dysplasia located at their lateral/ventral tongue [33]. K1 expression also significantly correlated with the progressive grade of dysplasia. The staining intensity as well as percentage of K1 positive SMF tissues increased with increase in the degree of fibrosis. These results collectively suggest that K1 expression levels are indicative of degree of dysplasia and fibrosis. Further, in oral SCC K1 expression significantly correlated with tumor size, nodal metastasis, bone and skin involvement and local recurrence and inversely correlated with patient's survival. However, Fillies group [15] did not find significant correlation between K1 expression and tumor size, nodal metastasis and patient's survival. Previously, K1 expression has been shown in well differentiated tumors and as the grade of the tumor increased, its expression was down regulated [26]. However, in this study we have detected K1 expression in the well, moderate as well as poorly differentiated tumors and intense immunolabeling was seen in higher grades of tumors. Thus, our results are at variance with reports from other laboratories. These differences probably can be explained by the fact that these reports are from the countries where tobacco chewing is not a major risk factor.

Other important observation from our earlier studies was aberrant expression of K8 and/or K18 in precancerous lesions as well as SCC of oral mucosa [18–20]. Glandular epithelia specific keratins 8/18 are normally not expressed in stratified epithelia [34]. We have shown the expression of this keratin pair in fetal buccal mucosa and tongue epithelium till 27 weeks of gestation [35].

As shown in case of K1, the aberrant expression of K8/18 also significantly correlated with non-homogeneous versus homogeneous leukoplakia. Further K8/18 expression also correlated with progressive grade of dysplasia and K18 with progressive grade of fibrosis. This indicates that aberrant expression of K8 and /or K18 could be used to assess the degree of dysplasia/fibrosis and may further be correlated with malignant potential of the tissues.

It is known that SMF is a disorder of underlined connective tissue and it is proved that exposure of tobacco/areca nut causes epithelial cells to stimulate cytokines, and these cytokines are the real initiator of fibrosis [36]. Fibroblasts have been shown to be responsible for the structural and functional alterations of oral mucosa [37]. These reports suggest that both the compartments-connective tissue and epithelium have mutual influence on their cellular and functional regulators. Hence, occurrence of alterations in keratin expression pattern in fibrotic mucosa could be the cause of early molecular changes occurring in both the compartments.

Our in vitro study has shown that K8/18 in some way contributes to the malignant transformation of stratified epithelial cells [38]. Results of the studies conducted by Casanova et al. [39] using K8 transgenic mice also support this finding. They have shown down-regulation of K5 in the epidermal cells where K8 transgene was expressed. Hence, it was important to analyze correlations between loss of K5 expression and gain of K1, K8, 18 expression with clinicopathological parameters of the patients to evaluate diagnostic and prognostic implications of these two events. However, in the present study K5 non-expression was seen only in 29/304 samples. Therefore, we have not compared K5 non-expression with aberrant expression of K1, K8 and K18. We have evaluated clinical significance of aberrantly expressed K1, K8 and K18 in combinations of any one positive, any two positive and all positive which significantly correlated with overall survival as well as recurrence free survival. We also noticed the trend that the risk of tumor recurrence increased, with increased number of markers combined together (Table 6). This indicates that a combination of these markers has better prognostic value as compared to any of these markers alone in OSCC patients.

One of our important observations is presence of only one partner of this keratin pair in different subsets of cell populations of leukoplakia, SMF as well as SCC. Thus we see de-regulation of keratin pair expression in diseased condition. As is well known in keratin biology, keratins can form functional filaments only when they are expressed in specific pairs. Another observation in this study is the intense immunolabeling of K8/18 in the invasive front of the high grade tumors. It is known that several molecular events of importance for tumor spread occur at the tumor-host interface [40]. In this context, this observation is of particular importance to predict the biological aggressiveness of the tumor and could be taken into account during oral cancer management.

As K5 non-expression and aberrant expression of K1, K8 and K18 were not detected in all the precancerous lesions, it was important to know whether those who demonstrated these two events are the high-risk lesions for malignant conversion over a period of time. However, majority of our patients with premalignant lesions were migrants from different states of India, with lack of stable contact details. Therefore, it was not possible for

us to obtain the follow-up of the disease status of these patients. In this regard, it will be important to conduct further studies with systematic, periodic clinical follow-up of high risk oral cavity lesions.

The altered keratin expression pattern was also seen in the cut margin tissues of the tumors, indicating that surrounding areas of the tumor although pathologically free from malignancy, show alterations at molecular level. In our previous study, we have found correlation between the expression of K8, K18 and K19 in the tumor surrounding areas and postsurgery elevated levels of their fragmented proteins in the sera of respective OSCC patients. This correlation showed association with development of local recurrence and poor survival of OSCC patients [21]. These observations further indicate that alterations in keratin expression pattern even in cut margin tissues may add value in histopathological diagnosis of progressive grade of OSCC.

Thus in summary, we have detected altered K1, K5, K8 and K18 expression pattern in oral leukoplakia, submucous fibrosis and tumor tissues. Further, significant correlation between aberrant expression of K1, K8 and K18 and non-expression of K5 with clinical subtypes of leukoplakia was also seen. It is important to distinguish the homogenous and non-homogeneous leukoplakia lesions at early stage since it will help clinicians in determination of treatment protocols such as laser excision. We found statistical correlation between altered keratin expression patterns and histopathological progressive grade of dysplasia. At present histopathological diagnosis of dysplasia has remained subjective and such biomarkers will prove useful in minimizing this subjectivity especially when their presence or absence is important rather than their quantitation. Further, significant correlation was also found between the combinations of keratin markers-K1, K8 and K18 and overall survival as well as recurrence (local) free survival in patients with OSCC. Since tumor recurrence is one of the leading causes of death in oral cancer patients, this correlation will have important prognostic implications.

## CONCLUSION

This is the first comprehensive study evaluating statistical correlation between altered keratin expression pattern and clinicopathological parameters of patients with both oral potentially malignant lesions and malignant tumors. Our findings suggest that the alterations in keratin expression pattern may prove useful as surrogate markers for the diagnosis of oral potentially malignant disorders and may also have prognostic value in patients with oral cancer.

\*\*\*\*\*

## Acknowledgements

We acknowledge grant support from Lady Tata Memorial Trust, Mumbai, India (Grant No. 1921). We thank Dr. Vaishali Natu from Nair Dental Hospital for providing leukoplakia and submucous fibrosis specimens and Dr. Swapna Deniz from D.Y.Patil Dental College and Hospital, Navi-Mumbai-India for providing leukoplakia specimens. We also thank Mrs. Namrata Mandavkar and Dr. Shilpi Sharma for retrieving patient's clinical information.

## Author Contributions

Sharada Sawant – Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Critical revision of the article, Final approval of the version to be published

Milind Vaidya – Analysis and interpretation of data, Critical revision of the article, Final approval of the version to be published

Devendra Chaukar – Analysis and interpretation of data, Critical revision of the article, Final approval of the version to be published

Prakash Gangadaran – Acquisition of data, Critical revision of the article, Final approval of the version to be published

Archana Kumari Singh – Acquisition of data, Critical revision of the article, Final approval of the version to be published

Siddheshwar Rajadhyax – Acquisition of data, Drafting the article, Final approval of the version to be published

Sadhana Kannan – Analysis and interpretation of data, Drafting the article, Final approval of the version to be published

Padmavathi A. – Analysis and interpretation of data, Drafting the article, Final approval of the version to be published

Shubhada Kane – Analysis and interpretation of data, Critical revision of the article, Final approval of the version to be published

Sandeep Pagare – Analysis and interpretation of data, Critical revision of the article, Final approval of the version to be published

Ranganathan Kannan – Analysis and interpretation of data, Critical revision of the article, Final approval of the version to be published

Anil D'Cruz – Analysis and interpretation of data, Critical revision of the article, Final approval of the version to be published

## Guarantor

The corresponding author is the guarantor of submission.

## Conflict of Interest

Authors declare no conflict of interest.

**Copyright**

© 2014 Sharada Sawant et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

**REFERENCES**

1. Tanaka T, Ishigamori R. Understanding carcinogenesis for fighting oral cancer. *J Oncol* 2011;2011:603740.
2. Sankaranarayanan R. Oral cancer in india: An epidemiologic and clinical review. *Oral Surg Oral Med Oral Pathol* 1990 Mar;69(3):325–30.
3. Pindborg JJ, Smith CJ, Van der Waal. Histological typing of cancer and precancer of the oral mucosa. Berlin: Springer-verlag. 2nd ed, 1997 pp. 224–7.
4. Gupta PC, Bhonsle RB, Murti PR, Daftary DK, Mehta FS, Pindborg JJ. An epidemiologic assessment of cancer risk in oral precancerous lesions in india with special reference to nodular leukoplakia. *Cancer* 1989 Jun 1;63(11):2247–52.
5. Ahmad MS, Ali SA, Ali AS, Chaubey KK. Epidemiological and etiological study of oral submucous fibrosis among gutkha chewers of patna, bihar, india. *J Indian Soc Pedod Prev Dent* 2006 Jun;24(2):84–9.
6. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. *Oral Oncol* 2009 Apr-May;45(4-5):317–23.
7. Kujan O, Khattab A, Oliver RJ, Roberts SA, Thakker N, Sloan P. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: An attempt to understand the sources of variation. *Oral Oncol* 2007 Mar;43(3):224–31.
8. Mehrotra R, Gupta DK. Exciting new advances in oral cancer diagnosis: Avenues to early detection. *Head Neck Oncol* 2011 Jul 28;3:33.
9. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. *CA Cancer J Clin* 2005 Jan-Feb;55(1):10–30.
10. Rath GK. Molecular markers in the head and neck cancers: Are we there yet? *J Cancer Res Ther* 2013 Jan-Mar;9(1):1–2.
11. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. *N Engl J Med* 2001 Apr 26;344(17):1323–6.
12. Chaw SY, Majeed AA, Dalley AJ, Chan A, Stein S, Farah CS. Epithelial to mesenchymal transition (emt) biomarkers—e-cadherin, beta-catenin, apc and vimentin—in oral squamous cell carcinogenesis and transformation. *Oral Oncol* 2012 Oct;48(10):997–1006.
13. Schliephake H. Prognostic relevance of molecular markers of oral cancer—a review. *Int J Oral Maxillofac Surg* 2003 Jun;32(3):233–45.
14. Sawant SS, Naresh KN, D’Cruz A, Ogale SB, Vaidya MM. Demonstration of cytokeratin-5 non-expression in tobacco related oral carcinogenesis—use of reverse

transcriptase polymerase chain reaction as a sensitive assay. *Oral Oncol* 2003 Dec;39(8):789–5.

15. Spruance SL, Reid JE, Grace M, Samore M: Hazard ratio in clinical trials. *Antimicrobial agents and chemotherapy* 2004;48:2787–92.
16. Nanda KD, Ranganathan K, Devi U, Joshua E. Increased expression of ck8 and ck18 in leukoplakia, oral submucous fibrosis, and oral squamous cell carcinoma: An immunohistochemistry study. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2012 Feb;113(2):245–3.
17. Ranganathan K, Kavitha R, Sawant SS, Vaidya MM. Cytokeratin expression in oral submucous fibrosis—an immunohistochemical study. *J Oral Pathol Med* 2006 Jan;35(1):25–32.
18. Vaidya MM, Borges AM, Pradhan SA, Rajpal RM, Bhisey AN. Altered keratin expression in buccal mucosal squamous cell carcinoma. *J Oral Pathol Med* 1989 May;18(5):282–6.
19. Vaidya MM, Sawant SS, Borges AM, Ogale SB, Bhisey AN. Cytokeratin expression in precancerous lesions of the human oral cavity. *Oral Oncol* 1998 Jul;34(4):261–4.
20. Vaidya MM, Borges AM, Pradhan SA, Bhisey AN. Cytokeratin expression in squamous cell carcinomas of the tongue and alveolar mucosa. *Eur J Cancer B Oral Oncol* 1996 Sep;32B(5):333–6.
21. Sawant SS, Chaukar DA, Joshi SS, et al. Prognostic value of tissue polypeptide antigen in oral squamous cell carcinoma. *Oral Oncol* 2011 Feb;47(2):114–20.
22. Bland JM, Altman DG: The logrank test. *Bmj* 2004;328:1073.
23. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratin: Patterns of expression in normal epithelia, tumors and cultured cells. *Cell* 1982 Nov;31(1):11–24.
24. Ogden GR, Chisholm DM, Leigh IM, Lane EB. Cytokeratin profiles in dyskeratosis congenita: An immunocytochemical investigation of lingual hyperkeratosis. *J Oral Pathol Med* 1992 Sep;21(8):353–7.
25. Skerrow D, Hunter I. Protein modifications during the keratinisation of normal and psoriatic human epidermis. *Biochim Biophys Acta* 1978 Dec 20;537(2):474–84.
26. Vigneswaran N, Peters KP, Hornstein OP, Haneke E. Comparison of cytokeratin, filaggrin and involucrin profiles in oral leukoplakias and squamous carcinomas. *J Oral Pathol Med* 1989 Aug;18(7):377–90.
27. Schulz J, Ermich T, Kasper M, Raabe G, Schumann D. Cytokeratin pattern of clinically intact and pathologically changed oral mucosa. *Int J Oral Maxillofac Surg* 1992 Feb;21(1):35–9.
28. Alam H, Bhate AV, Gangadaran P, et al. Fascin overexpression promotes neoplastic progression in oral squamous cell carcinoma. *BMC Cancer* 2012 Jan 20;12:32.
29. Morgan PR, Su L. Intermediate filaments in oral neoplasia. I. Oral cancer and epithelial dysplasia. *Eur J Cancer B Oral Oncol* 1994 May;30B(3):160–6.
30. Gupta PC, Murti PR, Bhonsle RB, Mehta FS, Pindborg JJ. Effect of cessation of tobacco use on the incidence

- of oral mucosal lesions in a 10-year follow-up study of 12,212 users. *Oral Dis* 1995 Mar;1(1):54–8.
31. Misra V, Singh PA, Lal N, Agarwal P, Singh M. Changing pattern of oral cavity lesions and personal habits over a decade: Hospital based record analysis from allahabad. *Indian J Community Med* 2009 Oct;34(4):321–5.
  32. Pandey M, Thomas G, Somanathan T, et al. Evaluation of surgical excision of non-homogeneous oral leukoplakia in a screening intervention trial, kerala, india. *Oral Oncol* 2001 Jan;37(1):103–9.
  33. Liu W, Shi LJ, Wu L, et al. Oral cancer development in patients with leukoplakia--clinicopathological factors affecting outcome. *PLoS One* 2012;7(4):e34773.
  34. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratin: Patterns of expression in normal epithelia, tumors and cultured cells. *Cell* 1982 Nov;31(1):11–24.
  35. Vaidya MM, Sawant SS, Borges AM, Naresh NK, Purandare MC, Bhisey AN. Cytokeratin expression in human fetal tongue and buccal mucosa. *J Biosci* 2000 Sep;25(3):235–42.
  36. Raul U, Sawant S, Dange P, Kalraiya R, Ingle A, Vaidya M. Implications of cytokeratin 8/18 filament formation in stratified epithelial cells: Induction of transformed phenotype. *Int J Cancer* 2004 Sep 20;111(5):662–8.
  37. Casanova ML, Bravo A, Martínez-Palacio J, et al. Epidermal abnormalities and increased malignancy of skin tumors in human epidermal keratin 8-expressing transgenic mice. *FASEB J* 2004 Oct;18(13):1556–8.
  38. Haque MF, Harris M, Meghji S, Barrett AW. Immunolocalization of cytokines and growth factors in oral submucous fibrosis. *Cytokine* 1998 Sep;10(9):713–9.
  39. Lalli A, Tilakaratne WM, Ariyawardana A, et al. An altered keratinocyte phenotype in oral submucous fibrosis: Correlation of keratin k17 expression with disease severity. *J Oral Pathol Med* 2008 Apr;37(4):211–20.
  40. Bryne M. Is the invasive front of an oral carcinoma the most important area for prognostication? *Oral Dis* 1998 Jun;4(2):70–7.

Access full text article on  
other devices



Access PDF of article on  
other devices

